Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with SchizophreniaBusiness Wire • 08/31/21
Showcasing Teva's Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache.Business Wire • 08/30/21
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive DyskinesiaBusiness Wire • 08/20/21
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/28/21
Teva Stock Falls After COVID-19 Impacts Q2 Top And Bottomline; Lowers FY21 OutlookBenzinga • 07/28/21
Teva revenue falls short of estimates, lowers guidance as pandemic continue to weighMarket Watch • 07/28/21
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent AnalysisBusiness Wire • 07/28/21
Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021Business Wire • 07/01/21